Literature DB >> 29502353

Novel TLE4-NTRK2 fusion in a ganglioglioma identified by array-CGH and confirmed by NGS: Potential for a gene targeted therapy.

Nitya Prabhakaran1, Miguel A Guzman2, Pournima Navalkele3, Edna Chow-Maneval4, Jacqueline R Batanian5.   

Abstract

Gangliogliomas are rare neoplasms of the central nervous system that mostly originate in the temporal lobe and are associated with seizures. Literature mentions that BRAF mutations are most commonly associated with gangliogliomas. We discuss a unique case of ganglioglioma originating in the posterior fossa that showed multiple losses and a unique interstitial deletion at 9q21 by an array-comparative genome hybridization (array-CGH). The deletion led to a novel molecular fusion (TLE4-NTRK2) which was confirmed by next generation sequencing and provides a potential for a gene-targeted therapy.
© 2018 Japanese Society of Neuropathology.

Entities:  

Keywords:  NTRK fusions; deletion; ganglioglioma; microarray; targeted therapy

Year:  2018        PMID: 29502353     DOI: 10.1111/neup.12458

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  10 in total

Review 1.  Pathologic and molecular aspects of anaplasia in circumscribed gliomas and glioneuronal tumors.

Authors:  Elisabet Pujadas; Liam Chen; Fausto J Rodriguez
Journal:  Brain Tumor Pathol       Date:  2019-03-11       Impact factor: 3.298

Review 2.  TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.

Authors:  Shivaani Kummar; Ulrik N Lassen
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

Review 3.  Testing algorithm for identification of patients with TRK fusion cancer.

Authors:  Frédérique Penault-Llorca; Erin R Rudzinski; Antonia R Sepulveda
Journal:  J Clin Pathol       Date:  2019-05-09       Impact factor: 3.411

Review 4.  Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer.

Authors:  Derek Wong; Stephen Yip; Poul H Sorensen
Journal:  Pathol Oncol Res       Date:  2019-06-29       Impact factor: 3.201

5.  Neurotrophic Receptor Tyrosine Kinase 2 (NTRK2) Alterations in Low-Grade Gliomas: Report of a Novel Gene Fusion Partner in a Pilocytic Astrocytoma and Review of the Literature.

Authors:  Siobhan S Pattwell; Eric Q Konnick; Yajuan J Liu; Rebecca A Yoda; Laligam N Sekhar; Patrick J Cimino
Journal:  Case Rep Pathol       Date:  2020-01-30

Review 6.  Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.

Authors:  Susan J Hsiao; Ahmet Zehir; Anthony N Sireci; Dara L Aisner
Journal:  J Mol Diagn       Date:  2019-05-07       Impact factor: 5.568

Review 7.  New Approaches with Precision Medicine in Adult Brain Tumors.

Authors:  Annette Leibetseder; Matthias Preusser; Anna Sophie Berghoff
Journal:  Cancers (Basel)       Date:  2022-01-29       Impact factor: 6.639

Review 8.  The oncogenic fusion landscape in pediatric CNS neoplasms.

Authors:  Mieke Roosen; Zelda Odé; Jens Bunt; Marcel Kool
Journal:  Acta Neuropathol       Date:  2022-02-15       Impact factor: 15.887

9.  NTRK3 gene fusion in an adult ganglioglioma: illustrative case.

Authors:  Sebastian Rubino; John Lynes; Paul McBride; Solmaz Sahebjam; Sepideh Mokhtari; Joaquim M Farinhas; Arie Perry; Robert Macaulay; Michael A Vogelbaum
Journal:  J Neurosurg Case Lessons       Date:  2022-01-31

10.  Molecular and clinicopathologic features of gliomas harboring NTRK fusions.

Authors:  Matthew Torre; Varshini Vasudevaraja; Jonathan Serrano; Michael DeLorenzo; Seth Malinowski; Anne-Florence Blandin; Melanie Pages; Azra H Ligon; Fei Dong; David M Meredith; MacLean P Nasrallah; Craig Horbinski; Sonika Dahiya; Keith L Ligon; Mariarita Santi; Shakti H Ramkissoon; Mariella G Filbin; Matija Snuderl; Sanda Alexandrescu
Journal:  Acta Neuropathol Commun       Date:  2020-07-14       Impact factor: 7.578

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.